Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Thromb Haemost. 2019 Jun 20;17(8):1384–1396. doi: 10.1111/jth.14521

Figure 1. Recombinant soluble SCARA5 binds to VWF.

Figure 1

(A) Dose-dependent binding of soluble human plasma-derived VWF to immobilized recombinant, purified soluble human SCARA5 by solid phase assay. (B) Binding of soluble human plasma-derived VWF (1 U/mL) to immobilized recombinant human SCARA5 (5 μg/mL) that was pre-incubated for 30 minutes at room temperature with anti-human SCARA5 antibodies PA5–23551 (1:5 dilution), LS-B5013 (100 ug/mL), AF4900 (100 ug/mL), and αh-SR5.2 (40 ug/mL). (C) Binding of soluble human recombinant FVIII (10 U/mL) to immobilized recombinant human SCARA5 (5 μg/mL) in the presence or absence of human plasma-derived VWF (1 U/mL). (D) Binding of soluble human plasma-derived VWF (1 U/mL) to immobilized recombinant, purified human SCARA5 (5 μg/mL) in the presence or absence of calcium (2 mM), magnesium (2 mM), and EDTA (10 mM). (E) Binding of soluble human plasma-derived VWF (0.5 U/mL) to immobilized recombinant human SCARA5 (5 μg/mL) preincubated with scavenger receptor ligands short or long-chain PolyP (100 μg/mL), PolyI (100 μg/mL), PolyG (1 mg/mL), dextran sulfate (DS) (2 mg/mL) or chondroitin sulfate (CS) (2 mg/mL) for 30 minutes at 37°C.